1 / 15

Drug Stores

Drug Stores. Trevor Yerrick Section 2. Quick Background. Drug Store Industry Traditional vs. In-store Pharmacy Benefit Managers (PBMs) “Nation’s largest drugstore chain” 8,582 locations, including 8,116 drug stores 2013: $72.2 B in sales, $45.5 B in prescription sales

tate
Télécharger la présentation

Drug Stores

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Stores Trevor Yerrick Section 2

  2. Quick Background • Drug Store Industry • Traditional vs. In-store • Pharmacy Benefit Managers (PBMs) • “Nation’s largest drugstore chain” • 8,582 locations, including 8,116 drug stores • 2013: $72.2 B in sales, $45.5 B in prescription sales • Recent trend of expansion through acquisitions • Alliance Boots (45%) acquisition in 2012, option to purchase remaining 55% in 2015

  3. Steps to Using Multiples • 1. Select summary performance measure to use as basis for valuation • No single right measure • EPAT, NI, and Drug Sales (industry-specific multiple) chosen as performance measures • Tough to determine – no two firms are in exactly the same business • Easiest numbers to grasp

  4. 2. Select Comparable Companies

  5. 3. Compute Market Multiples EPAT Multiple Enterprise Value = EPAT * EPAT Market Multiple Equity Value = Enterprise Value - NFL

  6. 3. Compute Market Multiples NI Multiple Equity Value = NI* NI Market Multiple

  7. 3. Compute Market Multiples Industry-Specific Multiple (Drug Sales) Equity Value = Drug Sales * Drug Sales Multiple

  8. Adjustments of Comparables • No pure competitors in the industry • Walgreens = only drug store chain • CVS Caremark = drug store chain and PBM • Express Scripts = only PBM • Wal-Mart = over-aggregated, too large • Best option = remove Express Scripts from analysis • CVS and Wal-Mart have retail pharmacies (WAG’s core business)

  9. Adjusted Market Multiples EPAT Multiple Equity value per share: decreased by 40%

  10. Adjusted Market Multiples NI Multiple Equity value per share: decreased by 34%

  11. Adjusted Market Multiples Industry-Specific Multiple (Drug Sales) Equity value per share: increased by 36%

  12. 4. & 5. Compute Value Using Multiples • Combining Multiples (with and without ESRX) • Equity value per share

  13. Recommendation for Investors • Based on this analysis… BUY • The closing price on 1/23/14 = $58.35 • Significantly undervalued compared to the averages of the market multiples • With ESRX included: $80.88 • Without ESRX: $76.82

  14. Confidence in Multiples Method Valuation • Not very high…. for a number of reasons • Theoretically difficult • Assume comparable companies are accurately valued, but Walgreens is not • No perfect competitor for Walgreens in the industry • Difficult to determine which comparable companies to include/exclude from multiples analysis • 2013 figures vs. 2012 data of comparable firms • Could benefit from NEA multiple and other multiples utilizing enterprise value • Prevents leverage from affecting the valuation estimates

  15. Questions?

More Related